36 completed. 36 Phase 2, 8 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 36 |
| Phase 1 | 8 | Completed 8 |
| Phase 3 | 2 | Completed 2 |
Follow Communication Disorders: new trials by email Literature Review of Communication Disorders trials Research Report on Communication Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders Zinc Acetate Dihydrate - GNAO1, Dystonia | Phase 2 | Completed | Children's University Hospital Cologne, Germany | 13 | 2024-08-02 | 2026-02-03 |
| The Effect of Prior Learning on Word Learning VAULT Phase 4 - Language Development Disorders | Phase 2 | Completed | University of Arizona | 22 | 2023-06-01 | 2025-06-27 |
| Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA) Transcranial Direct Current Stimulation (tDCS), Word-Naming Activity - Primary Progressive Aphasia | Phase 2 | Completed | NYU Langone Health | 11 | 2022-12-24 | 2024-09-19 |
| A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) NOE-105, Placebo - Childhood-Onset Fluency Disorder | Phase 2 | Completed | Noema Pharma AG | 75 | 2022-07-25 | 2026-02-20 |
| Visual Acoustic Biofeedback for RSE Via Telepractice Visual-Acoustic Biofeedback Treatment, No Treatment - Speech Sound Disorder | Phase 2 | Completed | Montclair State University | 40 | 2022-01-15 | 2026-02-17 |
| Dopaminergic Therapy for Frontotemporal Dementia Patients Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch, Placebo - Frontotemporal Dementia, Dementia | Phase 2 | Completed | I.R.C.C.S. Fondazione Santa Lucia | 75 | 2021-06-03 | 2024-10-22 |
| Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely) Ecopipam, Placebo - Childhood-Onset Fluency Disorder (Stuttering) | Phase 2 | Completed | Emalex Biosciences Inc. | 68 | 2020-10-22 | 2026-09-23 |
| Speech Entrainment for Aphasia Recovery SET (Speech Entrainment Therapy) 3 weeks, SET (Speech Entrainment Therapy) 4.5 weeks, SET (Speech Entrainment Therapy) 6 weeks - Aphasia, Aphasia Non Fluent | Phase 2 | Completed | Medical University of South Carolina | 80 | 2020-08-21 | 2025-11-14 |
| Treating Primary Progressive Aphasia (PPA) Using High-definition tDCS high-definition transcranial direct current stimulation, modified constraint-induced language therapy - Primary Progressive Aphasia | Phase 2 | Completed | University of Pennsylvania | 76 | 2020-08-17 | 2026-10-19 |
| Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). - Language Delay, Language; Developmental Disorder, Expressive | Phase 1 / Phase 2 | Completed | Russian Academy of Medical Sciences | 14 | 2020-02-01 | 2022-05-02 |
| Maximizing Outcomes for Preschoolers With Developmental Language Disorders the Enhanced Milieu Teaching-Sentence Focus - Developmental Language Disorder | Phase 2 | Completed | Northwestern University | 108 | 2019-04-04 | 2026-08-19 |
| Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Chronic Aphasia Active TMS, Sham TMS, CILT - Aphasia | Phase 2 | Completed | H. Branch Coslett | 86 | 2019-03-28 | 2025-10-14 |
| PCT for Speech, Language, and Cognitive Intervention in Stroke Patients PCT, Workbooks - Aphasia, Acquired | Phase 2 | Completed | The Learning Corp | 36 | 2019-03-18 | 2020-07-27 |
| A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome BPN14770, Placebo - Fragile X Syndrome, FXS | Phase 2 | Completed | Tetra Discovery Partners | 30 | 2018-07-09 | 2024-12-19 |
| Building Sentences With Preschoolers Who Use AAC AAC Generative Language Intervention, Standard of Care / Business as Usual - Down Syndrome, Speech and Language Disorder | Phase 2 | Completed | University of Central Florida | 70 | 2018-05-11 | 2024-01-08 |
| Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study HD-tDCS (Soterix Medical, Active), HD-tDCS (Soterix Medical, Sham) - Chronic Aphasia | Phase 2 | Completed | Soterix Medical | 58 | 2015-07-01 | 2023-12-05 |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
| Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine Fluoxetine - Selective Mutism, Social Anxiety | Phase 2 | Completed | Michigan State University | 6 | 2014-01-01 | 2022-05-18 |
| Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer pre, during and pos-treatment swallowing exercises - Head Neck Cancer, Swallowing Disorders | Phase 2 | Completed | Barretos Cancer Hospital | 94 | 2012-07-01 | 2017-06-28 |
| Brain Stimulation and Aphasia Treatment Activa Dose II Real tDCS, Activa Dose II Sham tDCS - Aphasia | Phase 2 | Completed | University of South Carolina | 74 | 2012-04-01 | 2019-08-20 |
Showing 20 of 36. Sign in to see all of them.
Aphasia (11) · Learning Disabilities (7) · Stroke (7) · Language (4) · Language Development Disorders (4) · Language Disorders (4) · Aphasia, Primary Progressive (3) · Attention Deficit Disorder with Hyperactivity (3) · Central Nervous System Diseases (3) · Developmental Disabilities (3) · Mental Disorders (3) · Mutism (3) · Aphasia, Broca (2) · Autism Spectrum Disorder (2)
Pathological Conditions, Signs and Symptoms (34) · Signs and Symptoms (34) · Neurobehavioral Manifestations (33) · Neurologic Manifestations (33) · Nervous System Diseases (32) · Language Disorders (22) · Mental Disorders (20) · Neurodevelopmental Disorders (20) · Speech Disorders (16) · Brain Diseases (12) · Central Nervous System Diseases (11) · Behavior (7) · Cardiovascular Diseases (7) · Cerebrovascular Disorders (7)
Animal Assisted Therapy (1) · BPN14770 (1) · Commerce (1) · Fluoxetine (1) · Lead (1) · Methods (1) · SET protein, human (1) · Standard of Care (1) · Therapeutics (1) · Transcranial Direct Current Stimulation (1) · Umbilical Cord Clamping (1) · Zinc Acetate (1) · carbidopa, levodopa drug combination (1) · ecopipam (1) · pagoclone (1)
Barretos Cancer Hospital (1) · Children's Hospitals and Clinics of Minnesota (1) · Children's University Hospital Cologne, Germany (1) · Climb Up Kids (1) · Emalex Biosciences Inc. (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Governors State University (1) · H. Branch Coslett (1) · I.R.C.C.S. Fondazione Santa Lucia (1) · Lamar University (1) · Medical University of South Carolina (1) · Michigan State University (1) · MindFrame, Inc. (1) · Montclair State University (1)
United States (28) · Germany (2) · Australia (1) · Brazil (1) · Hong Kong (1) · India (1) · Italy (1) · Norway (1) · Russia (1)
Abhishek Datta, Ph.D (1) · Alessandro Martorana, MD, PhD (1) · Alexander A Ostanin, MD, PhD (1) · Alexandre Jacinto, MD (1) · Ann Kaiser, PhD (1) · Atul R Mahableshwarkar, MD, DFAPA (1) · Bruce Crosson, PhD (1) · Catherine H Balthazar, PhD (1) · Cheryl M Scott, PhD (1) · Connie Kasari, PhD (1) · Devendra Mehta, MBBS MSC MRCP (1) · Elaine R. Hitchcock, PhD (1) · Elena R Chernykh, MD, PhD (1) · Gayatri Devi, MD (1)
PMID 20145986, PMID 23106988, PMID 25267381, PMID 26547399, PMID 29357099, PMID 29954605, PMID 30128538, PMID 32878377, PMID 33643204, PMID 33927413, PMID 40277885, PMID 40809903, PMID 42542632
R01DC007387 (1), R01DC007660 (1), R01DC015642 (1), R01DC016321 (1), R01DC016800 (1), R15DC009027 (1), R15DC019775 (1), R44NS092144 (1), U01DC011739 (1), U01DC017521 (1)